Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells). This phase of the study (phase I) will determine the highest dose of the study intervention that can be safely given.

Trial Details

NCT ID
NCT04886986
Phase
PHASE1
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 225Ac-J591
  • 177Lu-PSMA-617
  • 68Ga-PSMA-11
  • 177Lu-PSMA-I&T
Locations (sample)
  • Brooklyn, New York, United States|40.6501,-73.94958
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologically or cytologically confirmed adenocarcinoma of prostate
  • Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following crit…
  • ECOG performance status of 0-2
  • Have serum testosterone \< 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH/GnRH analogue (agonist/antagonist) if they ha…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →